Angiotensin converting enzyme inhibitors for cancer treatment?

Acta Oncologica

Volumn 43, Issue 2, 2004, Pages 142-152

  Lindberg, Henriette ^a   Nielsen, Dorte ^a   Jensen, Benny V ^a   Eriksen, Jens ^a   Skovsgaard, Torben ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AE 941; ANTINEOPLASTIC AGENT; BATIMASTAT; BENAZEPRIL; CAPTOPRIL; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT; FOSINOPRIL; GEMCITABINE; LISINOPRIL; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MOEXIPRIL; PACLITAXEL; PERINDOPRIL; PRINOMASTAT; QUINAPRIL; RAMIPRIL; REBIMASTAT; SPIRAPRIL; TANOMASTAT; TEMOCAPRIL; TRANDOLAPRIL; UNINDEXED DRUG; ZOFENOPRIL;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CELL CULTURE; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER THERAPY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CARCINOMA; DRUG EFFECT; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; IN VITRO STUDY; LUNG CARCINOMA; LUNG SMALL CELL CANCER; METASTASIS; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; STOMACH CARCINOMA;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL MOVEMENT; GENE EXPRESSION; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 1842678360     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860310022346     Document Type: Review

References (67)

1. White CM. Angiotensin-converting-enzyme inhibition in heart failure or after myocardial infarction. Am J Health-Syst Pharm 2000; 57: S18-25.
2. Jensen BV, Nielsen SL, Skovsgaard T. Treatment with angiotensin- converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet 1996; 347: 297-9.
3. Mathiesen ER, Hommel E, Hansen HP, Smidt UM, Parving HH. Randomised, controlled trial of long-term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. Br Med J 1999; 319: 24-5.
4. Parving H-H, Rossing P, Hommel E, Smidt UM. Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years' experience. Am J Kidney Dis 1995; 26: 99-107.
5. Manley HJ. Role of angiotensin-converting-enzyme inhibition in patients with renal disease. Am J Health-Syst Pharm 2000; 57: S12-7.
6. Piepho RW. Overview of the angiotensin-converting-enzyme inhibitors. Am J Health-Syst Pharm 2000; 57: S3-7.
7. Kerrigan JJ, Mansell JP, Sandy JR. Matrix turnover. J Orthodontics 2000; 27: 227-33.
8. Boudreau N, Bissell MJ. Extracellular matrix signaling: integration of form and function in normal and malignant cells. Curr Opin Cell Biol 1998; 10: 640-6.
9. Horwitz AR, Werb Z. Cell-to-cell contact and extracellular matrix cell adhesion and the extracellular matrix: recent progress and emerging themes. Curr Opin Cell Biol 1998; 10: 563-5.
10. Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, Darnell J. Integrating cells into tissues. In: Tenney S, ed. Molecular cell biology, 4th ed. New York: W. H. Freeman and Company; 2000. p. 968-1002.
11. Roskelley CD, Srebrow A, Bissel MJ. A hierarchy of ECM-mediated signalling regulates tissue-specific gene expression. Curr Opin Cell Biol 1995; 7: 736-47.
12. Fingleton B, Matrisian LM. Matrix metalloproteinases in cancer. In: Clendeninn NJ, Appelt K, eds. Matrix metalloproteinases in cancer therapy, 1st ed. Totowa, New Jersey: Humana Press; 2001. p. 85-112.
13. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Natl Rev Cancer 2002; 2: 657-72.
14. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol 2001; 13: 534-40.
15. Eccles SA, Box GM, Court WJ, Bone EA, Thomas W, Brown PD. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 1996; 56: 2815-22.
16. Alves F, Borchers U, Padge B, et al. Inhibitory effect of a matrix metalloproteinase inhibitor on growth and spread of human pancreatic ductal adenocarcinoma evaluated in an orthotopic severe combined immunodeficient (SCID) mouse model. Cancer Lett 2001; 165: 161-70.
17. Naglich JG, Jure-Kunkel M, Gupta E, et al. Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res 2001; 61: 8480-5.
18. Sledge GW, Jr, Qulali M, Goulet R, Bone EA, Fife R. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 1995; 87: 1546-50.
19. Anderson IC, Shipp MA, Docherty AJP, Teicher BA. Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res 1996; 56: 715-8.
20. Giavazzi R, Garofalo A, Ferri C, et al. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the anti-tumor activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res 1998; 4: 985-92.
21. Hojo K, Maki H, Sawada TY, Maekawa R, Yoshioka T. Augmented growth inhibition of B16-BL6 melanoma by combined treatment with a selective matrix metalloproteinase inhibitor, MMI-166, and cytotoxic agents. Anticancer Res 2002; 22: 3253-9.
22. Yamamoto A, Yano S, Shiraga M, et al. A third-generation matrix metalloproteinase (MMP) inhibitor (ONO-4817) combined with docetaxel suppresses progression of lung micro-metastasis of MMP-expressing tumor cells in nude mice. Int J Cancer 2003; 103: 822-8.
23. Hoekstra R, Eskens FA, Verweij J. Matrix metalloproteinase inhibitors: current developments and future perspectives. Oncologist 2001; 6: 415-27.
24. Drummond AH, Beckett P, Brown PD, et al. Preclinical and clinical studies of MMP inhibitors in cancer. Ann N Y Acad Sci 1999; 878: 228-35.
25. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001; 93: 178-93.
26. Shepherd FA, Sridhar SS. Angiogenesis inhibitors under study for the treatment of lung cancer. Lung Cancer 2003; 41(Suppl 1): S63-72.
27. Bramhall SR, Hallissey MT, Whiting J, et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 2002; 86: 1864-70.
28. Shepherd FA, Giaccone G, Seymour L, et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20: 4434-9.
29. King J, Zhao J, Clingan P, Morris D. Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, marimastat, in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects. Anticancer Res 2003; 23: 639-45.
30. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001; 19: 3447-55.
31. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002; 87: 161-7.
32. Smylie M, Mercier R, Aboulafia D, et al. Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer. Proc ASCO 2001; 20: 307a.
33. Bisset D, O'Byrne K, von Pawel J. Phase III study of the matrix metalloprotease inhibitor prinomastat in combination with gemcitabine and cisplatin in non-small cell lung cancer. Proc ASCO 2002; 21: 296a.
34. Moore MJ, Hamm J, Dancey J, et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 1: 3296-302.
35. Tierney GM, Griffin NR, Stuart RC, et al. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer. Eur J Cancer 1999; 35: 563-8.
36. Nemunaitis J, Poole C, Primrose J, et al. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res 1998; 4: 1101-9.
37. Brown PD, Giavazri R. Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann Oncol 1995; 6: 967-74.
38. Belotti D, Paganoni P, Giavazzi R. MMP inhibitors: experimental and clinical studies. Int J Biol Markers 1999; 14: 232-8.
39. Brown PD. Clinical studies with matrix metalloproteinase inhibitors. APMIS 1999; 107: 174-80.
40. White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy 1998; 18: 588-99.
41. McMurray J, Chopra M. Influence of ACE inhibitors on free radicals and reperfusion injury: pharmacological curiosity or therapeutic hope? Br J Clin Pharmacol 1991; 31: 373-9.
42. Gately S, Twardowski P, Stack MS, et al. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci USA 1997; 94: 10868-72.
43. Lorell BH. Role of angiotensin AT1, and AT2 receptors in cardiac hypertrophy and disease. Am J Cardiol 1999; 83: 48H-52H.
44. Siragy HM. AT1 and AT2 receptors in the kidney: role in disease and treatment. Am J Kidney Dis 2000; 36: S4-9.
45. Stoll M, Unger T. Angiotensin and its AT2 receptor: new insights into an old system. Regul Pept 2001; 99: 175-82.
46. Chen L, Re RN, Prakash O, Mondai D. Angiotensin-converting enzyme inhibition reduces neuroblastoma cell growth rate. Proc Soc Exp Biol Med 1991; 196: 280-3.
47. Small W, Jr, Molteni A, Kim YT, Taylor JM, Chen Z, Ward WF. Captopril modulates hormone receptor concentration and inhibits proliferation of human mammary ductal carcinoma cells in culture. Breast Cancer Res Treat 1997; 44: 217-24.
48. Hii S-I, Nicol DL, Gotley DC, Thompson LC, Green MK, Jonsson JR. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer 1998; 77: 880-3.
49. Nakagawa T, Kubota T, Kabuto M, Kodera T. Captopril inhibits glioma cell invasion in vitro: involvement of matrix metalloproteinases. Anticancer Res 1995; 15: 1985-9.
50. Reddy MK, Baskaran K, Molteni A. Inhibitors of angiotensin-converting enzyme modulate mitosis and gene expression in pancreatic cancer cells. Proc Soc Exp Biol Med 1995; 210: 221-6.
51. Kowalski J, Belowski D, Madej A, Herman ZS. Effects of thiorphan, bestatin and captopril on the Lewis lung carcinoma metastases in mice. Pol J Pharmacol 1995; 47: 423-7.
52. Kowalski J, Herman ZS. Captopril augments antitumor activity of cyclophosphamide in mice. Pol J Pharmacol 1996; 48: 281-5.
53. Prontera C, Mariani B, Rossi C, Poggi A, Rotilio D. Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int J Cancer 1999; 81: 761-6.
54. Yoshiji H, Kuriyama S, Kawata M, et al. The angiotensin-i-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 2001; 7: 1073-8.
55. Volpert OV, Ward WF, Lingen MW, et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996; 98: 671-9.
56. Sorbi D, Fadly M, Hicks R, Alexander S, Arbeit L. Captopril inhibits the 72 kDa and 92 kDa matrix metalloproteinases. Kidney Int 1993; 44: 1266-72.
57. Song JC, White CM. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet 2002; 41: 207-24.
58. Vrhovac B, Sarapa N, Bakran I, Huic M, Macolic-Sarinic V, Francetic I, et al. Pharmacokinetic changes in patients with oedema. Clin Pharmacokinet 1995; 28: 405-18.
59. Williams B, Baker AQ, Gallacher B, Lodwick D. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 1995; 25: 913-7.
60. Gilbert RE, Kelly DJ, Cox AJ, et al. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia 2000; 43: 1360-7.
61. Pupilli C, Lasagni L, Romagnani P, et al. Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. J Am Soc Nephrol 1999; 10: 245-55.
62. Wartenberg M, Budde P, De Marees M, et al. Inhibition of tumor-induced angiogenesis and matrix-metalloproteinase expression in confrontation cultures of embryoid bodies and tumor spheroids by plant ingredients used in traditional Chinese medicine. Lab Invest 2003; 83: 87-98.
63. Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998; 352: 179-84.
64. Friis S, Sorensen HT, Mellemkjaer L, et al. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 2001; 92: 2462-70.
65. Meier CR, Derby LE, Jick SS, Jick H. Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch Intern Med 2000; 160: 349-53.
66. Stahl M, Bulpitt MJ, Palmer AJ, Beevers DG, Coles EC, Webster J. Calcium channel blockers, ACE inhibitors, and the risk of cancer in hypertensive patients: a report from the Department of Health Hypertension Care Computing Project (DHCCP). J Hum Hypertens 2000; 14: 299-304.
67. Maschio G, Marcantoni C. Angiotensin converting enzyme inhibitors in nondiabetic renal disease. Curr Opin Nephrol Hypertens 1998; 7: 253-7.